Smith+Nephew Announces FDA 510(k) Clearance For Its New CATALYSTEM Primary Hip System
Portfolio Pulse from Benzinga Newsdesk
Smith+Nephew has received FDA 510(k) clearance for its new CATALYSTEM Primary Hip System, which is expected to enhance its product offerings in the orthopedic market.
July 16, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Smith+Nephew has received FDA 510(k) clearance for its new CATALYSTEM Primary Hip System, which is expected to enhance its product offerings in the orthopedic market.
The FDA 510(k) clearance is a significant regulatory milestone that allows Smith+Nephew to market its new CATALYSTEM Primary Hip System in the US. This is likely to enhance its product portfolio and potentially increase market share in the orthopedic sector.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100